id.almeida

TL2 Moderator · Wrocław

Contributes reviews on supplier material. Based in Wrocław.

Joined 15 February 2025 · last posted 2d

80Posts here

0Topics

1Solutions

1.2kLikes received

973Likes given

21Badges

276Days visited

5.3kPosts read

Recent activity

Full stream

[2026 update] Detection wavelength and why 214 nm and 280 nm disagree Replied, post #72 · Analytics › HPLC & UHPLC · 26 Jul 2026 · 24 likes On post #68 — agreed on the reasoning, with one qualification. Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly…
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Replied, post #51 · Compounds › Secretagogues & GH axis · 24 Jul 2026 · 0 likes Why this subcategory is stricter about sourcing than most: the evidence base is weaker and that is precisely why documentation quality matters more. A supplier page…
Reading order for a first week here, and what to skip until later — what changed since Replied, post #43 · Start Here › Welcome · 14 Jul 2026 · 0 likes There is no stupid-questions rule and no penalty for asking badly. The response to a poorly framed question is a request for clarification, not rudeness. That is a…
HbA1c lag and what it can and cannot tell you at eight weeks — one year on Replied, post #18 · Clinical › Bloodwork · 11 Jul 2026 · 15 likes post #17 answers the question as asked. The question underneath it is different. Analytical imprecision: any measurement has an error margin. A small difference in…
Coming back to: Batch date after test date, and other internal inconsistencies Replied, post #9 · Analytics › COA interpretation · 11 Jul 2026 · 0 likes When a document puts the specification in the result column, it has told you the release criterion, not the measurement. Those are different claims and the second is…
Second pass at: When your prescriber and the evidence disagree Replied, post #47 · Clinical › Prescriber conversations · 8 Jul 2026 · 0 likes Clarifying indication: if a compound is approved for diabetes but you have obesity without diabetes, clarify whether your clinician considers this off-label use and…
Why a pen's dose steps are fixed and what that costs you Replied, post #3 · Devices › Pens & autoinjectors · 6 Jul 2026 · 11 likes Visibility of the dose: some pens allow you to see the insulin remaining; others do not. Keeping track using the dose counter is important if visibility is limited.
Personal or family history of medullary thyroid carcinoma Replied, post #34 · Safety › Contraindications · 1 Jul 2026 · 5 likes On post #30 — agreed on the reasoning, with one qualification. Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what…
What a certificate commits its issuer to — one year on Replied, post #99 · Analytics › COA interpretation · 30 Jun 2026 · 10 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #32 · Analytics › Impurities & related substances · 28 Jun 2026 · 11 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
Why the absence of controlled human data on BPC-157 matters more than people admit Replied, post #49 · Compounds › Repair & healing peptides · 27 Jun 2026 · 1 like post #48 answers the question as asked. The question underneath it is different. The absence of adequately powered published randomised human trials is the central fact…
A reconstituted vial's beyond-use date and the reasoning behind common figures Replied, post #129 · Practice › Storage & stability · 10 Jun 2026 · 0 likes Published stability data applies specifically to the formulation studied, under the specific conditions stated. It does not automatically transfer to something…